Abstract
The treatment of systemic hypertension (HTN) in patients with Aortic stenosis (AS) requires a careful balance of lowering the systemic blood pressure without compromising vital organ perfusion and worsening of the symptoms of AS. Treatment of systemic HTN is beneficial because the combination of HTN and AS provides additional overload to the left ventricle. This leads to secondary Left ventricular hypertrophy (LVH), which has been shown to increase cardiovascular risks and mortality and thus early presentation of symptoms of AS. Additionally, presence of HTN may affect the accurate assessment of AS. Different treatment options are available, however no specific treatment guidelines have been established for patients with concomitant AS and HTN. Improved control of HTN is the key to prevent symptom progression and inadvertent early surgery. Angiotensin converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARB) appear to be beneficial. Reassessment of the aortic valve by echocardiography is recommended after HTN is well controlled before deciding on aortic valve replacement (AVR).
Keywords: Aortic stenosis, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, cardiovascular risks, hypertension, pharmacological therapy.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Volume: 13 Issue: 1
Author(s): Sucheta Gosavi, Rahul Channa and Debabrata Mukherjee
Affiliation:
Keywords: Aortic stenosis, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, cardiovascular risks, hypertension, pharmacological therapy.
Abstract: The treatment of systemic hypertension (HTN) in patients with Aortic stenosis (AS) requires a careful balance of lowering the systemic blood pressure without compromising vital organ perfusion and worsening of the symptoms of AS. Treatment of systemic HTN is beneficial because the combination of HTN and AS provides additional overload to the left ventricle. This leads to secondary Left ventricular hypertrophy (LVH), which has been shown to increase cardiovascular risks and mortality and thus early presentation of symptoms of AS. Additionally, presence of HTN may affect the accurate assessment of AS. Different treatment options are available, however no specific treatment guidelines have been established for patients with concomitant AS and HTN. Improved control of HTN is the key to prevent symptom progression and inadvertent early surgery. Angiotensin converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARB) appear to be beneficial. Reassessment of the aortic valve by echocardiography is recommended after HTN is well controlled before deciding on aortic valve replacement (AVR).
Export Options
About this article
Cite this article as:
Gosavi Sucheta, Channa Rahul and Mukherjee Debabrata, Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy, Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (1) . https://dx.doi.org/10.2174/187152571301150730114814
DOI https://dx.doi.org/10.2174/187152571301150730114814 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Multi-targeting Andrographolide and its Natural Analogs as Potential Therapeutic Agents
Current Topics in Medicinal Chemistry Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenetic Study of CYP2C19 Variation and Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Atherothromboticrisk Patients in Thailand
Current Pharmacogenomics and Personalized Medicine Neutralization of Interleukin-1β Reduces Vasospasm and Alters Cerebral Blood Vessel Density Following Experimental Subarachnoid Hemorrhage in Rats
Current Neurovascular Research Preoperative Levosimendan. A New Way for Organoprotection
Current Pharmaceutical Design The Cardiologist in the Periphery: Indications and Usefulness of Peripheral Artery Invasive Angiography in Patients Undergoing Coronary Angiography
Current Medical Imaging The Effects of Angiotensin II Signaling Blockade on Platelet Activity in Subjects with Hypertension
Current Hypertension Reviews Cardioprotection with Sildenafil: Implications for Clinical Practice
Current Medicinal Chemistry Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets Myocardial Insulin Resistance and Cardiac Complications of Diabetes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients
Current Medicinal Chemistry Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Oleic Acid Vesicles for Transdermal Delivery of Propranolol Hydrochloride: Development and Characterization
Current Drug Therapy The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Cyclophilins in Atherosclerosis: A New Therapeutic Target?
Current Pharmaceutical Design Adverse HBOC-Endothelial Dysfunction Synergism: A Possible Contributor to Adverse Clinical Outcomes?
Current Drug Discovery Technologies Angiotensin-TGF-β1 Crosstalk in Human Idiopathic Pulmonary Fibrosis:Autocrine Mechanisms in Myofibroblasts and Macrophages
Current Pharmaceutical Design (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Design, Synthesis and Biological Evaluation of Benzopyran Derivatives as KATP Channel Openers
Letters in Drug Design & Discovery